On Tuesday, Pyxis Oncology Inc (NASDAQ: PYXS) opened lower -8.62% from the last session, before settling in for the closing price of $1.16. Price fluctuations for PYXS have ranged from $0.99 to $6.18 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Company’s average yearly earnings per share was noted 6.31% at the time writing. With a float of $42.26 million, this company’s outstanding shares have now reached $59.45 million.
The extent of productivity of a business whose workforce counts for 50 workers is very important to gauge. In terms of profitability, gross margin is 84.98%, operating margin of -343.24%, and the pretax margin is -293.15%.
Pyxis Oncology Inc (PYXS) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Pyxis Oncology Inc is 28.94%, while institutional ownership is 40.70%. The most recent insider transaction that took place on Nov 26 ’24, was worth 174,364. In this transaction CFO & COO of this company bought 88,850 shares at a rate of $1.96, taking the stock ownership to the 1,199,143 shares.
Pyxis Oncology Inc (PYXS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.31 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.73% during the next five years compared to -118.72% drop over the previous five years of trading.
Pyxis Oncology Inc (NASDAQ: PYXS) Trading Performance Indicators
Check out the current performance indicators for Pyxis Oncology Inc (PYXS). In the past quarter, the stock posted a quick ratio of 7.33. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.05, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.10 in one year’s time.
Technical Analysis of Pyxis Oncology Inc (PYXS)
The latest stats from [Pyxis Oncology Inc, PYXS] show that its last 5-days average volume of 0.51 million was inferior to 0.62 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 54.25%. Additionally, its Average True Range was 0.10.
During the past 100 days, Pyxis Oncology Inc’s (PYXS) raw stochastic average was set at 1.70%, which indicates a significant decrease from 29.41% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.38% in the past 14 days, which was lower than the 116.87% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.3686, while its 200-day Moving Average is $2.7690. Now, the first resistance to watch is $1.1800. This is followed by the second major resistance level at $1.3000. The third major resistance level sits at $1.3600. If the price goes on to break the first support level at $1.0000, it is likely to go to the next support level at $0.9400. The third support level lies at $0.8200 if the price breaches the second support level.
Pyxis Oncology Inc (NASDAQ: PYXS) Key Stats
There are currently 59,466K shares outstanding in the company with a market cap of 63.03 million. Presently, the company’s annual sales total 0 K according to its annual income of -73,790 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -17,300 K.
